subscribeSubscribe
price-trendAsk Us
Adlai Nortye Announces Completion of Patient Enrollment in PIII of Buparlisib

Adlai Nortye Announces Completion of Patient Enrollment in PIII of Buparlisib
GLOBENEWSWIRE
17 Nov 2023
Share Share
Adlai Nortye`s Buparlisib Set to a Potential Treatment for Anti-PD-1 HNSCC

Adlai Nortye`s Buparlisib Set to a Potential Treatment for Anti-PD-1 HNSCC
PR NEWSWIRE
15 Mar 2019
Share Share
Novartis succeeds where Roche failed with PI3K breast cancer drug

Novartis succeeds where Roche failed with PI3K breast cancer drug
Piotr Wnuk PHARMAPHORUM
23 Aug 2018
Share Share
Novartis just boasted of a big PhIII PI3K success

Novartis just boasted of a big PhIII PI3K success
John Carroll ENDPTS
23 Aug 2018
Share Share
Novartis trial win lifts profile of new breast cancer drug

Novartis trial win lifts profile of new breast cancer drug
John Miller REUTERS
23 Aug 2018
Share Share
Adlai Nortye announces Results From Buparlisib study in HNSCC published

Adlai Nortye announces Results From Buparlisib study in HNSCC published
PR NEWSWIRE
30 Jul 2018
Share Share
FiercePharmaAsia—Biogen-Eisai, Otsuka, Samsung and more

FiercePharmaAsia—Biogen-Eisai, Otsuka, Samsung and more
Angus Liu FIERCE PHARMA
13 Jul 2018
Share Share
Novartis hands off buparlisib to China`s Adlai Noryte

Novartis hands off buparlisib to China`s Adlai Noryte
Amirah Al Idrus FIERCE BIOTECH
12 Jul 2018
Share Share
Novartis punts a late-stage PI3K drug to China’s biotechs

Novartis punts a late-stage PI3K drug to China’s biotechs
John Carroll ENDPTS
12 Jul 2018
Share Share